No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial

ML Grijsen, R Steingrover, FWNM Wit, S Jurriaans, Annelies Verbon, K Brinkman, Marchina Ende, R Soetekouw, F de Wolf, JMA Lange, H Schuitemaker, JM Prins

Research output: Contribution to journalArticleAcademicpeer-review

84 Citations (Scopus)
9 Downloads (Pure)


Background: The objective of this study was to assess the benefit of temporary combination antiretroviral therapy (cART) during primary HIV infection (PHI). Methods and Findings: Adult patients with laboratory evidence of PHI were recruited in 13 HIV treatment centers in the Netherlands and randomly assigned to receive no treatment or 24 or 60 wk of cART (allocation in a 1:1:1 ratio); if therapy was clinically indicated, participants were randomized over the two treatment arms (allocation in a 1:1 ratio). Primary end points were (1) viral set point, defined as the plasma viral load 36 wk after randomization in the no treatment arm and 36 wk after tr Conclusions: In this trial, temporary cART during PHI was found to transiently lower the viral set point and defer the restart of cART during chronic HIV infection.
Original languageUndefined/Unknown
JournalPLoS Medicine (print)
Issue number3
Publication statusPublished - 2012

Cite this